Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age13-35
SponsorJohns Hopkins University

About this trial

This research project is a randomized cross-over pilot trial which aims to test the efficacy of N-acetylcysteine (NAC) for the treatment of Repetitive Behaviors (RB) and self-injurious behavior (SIB) in patients with Cornelia de Lange Syndrome (CdLs).

NAC is a known anti-oxidative stress and neuroprotective agent, which has been shown to decrease the occurrence of SIB such as skin picking. NAC has also shown partial response in trials for compulsive behaviors in Obsessive Compulsive Disorder (OCD) and related disorders in autism.

Cornelia de Lange syndrome (CdLS) is a genetic disorder with autistic features, including RBs and SIB. In this randomized clinical trial, participants with CdLS will be blindly assigned one of two possible treatment arms: 1) placebo (8 weeks) and NAC (8 weeks); or 2) NAC (8 weeks) and placebo (8 weeks), with an intermediate 2-week washout period.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Ages 13 to 35 years

A diagnosis of CdLS as determined by a physician during routine care meeting the major and minor criteria from CdLS guidelines

Threshold criteria for the presence of RB/SIB as reported on initial screening Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders (CYBOCS-PDD) > 6 OR Aberrant Behavior Checklist (ABC) stereotypy subscale > 7)

Being able to attend 4 visits over the course of 18 weeks at the Johns Hopkins Hospital

Disqualifiers

Allergy to NAC

Allergy to Quinine

Contraindication to NAC (organ transplant; untreated or symptomatic gastric condition)

Need for another medication with which NAC is contraindicated (antibiotics)

Trial design

Design model

Crossover

Treatments tested in this trial

  • N-acetyl cysteine

    Drug

    Oral solution for N-acetyl cysteine is prepared in syringes and provided to the participants along with instructions on how to administer them.

  • Placebo

    Other intervention

    NAC Placebo-matching solution is prepared in syringes and provided to the participants along with instructions on how to administer them.

Treatment groups

10 Participants
are divided into 2 treatment groups
Group A: Group A: NAC 1800mg then PlaceboExperimental treatment 2 interventions
Group B: Group B: Placebo then NAC 1800mgExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Change in Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders (CYBOCS-PDD) repetitive behaviors measure score

CYBOCS-PDD scores range from a minimum of 0 to a maximum of 20, higher scores indicate greater symptom severity. Efficacy of the intervention would be assessed by ≥35% reduction in CYBOCS-PDD repetitive behaviors measure score.

Time frame
Baseline, week 2, week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18
2

Change in Aberrant Behavior Checklist (ABC) irritability self-injurious behaviors items score

The ABC irritability sub-scale consists of 15 items of which 3 focus on Self-injurious Behaviors (SIB). Each item takes scores ranging from a minimum of 0 to a maximum of 3. The overall score for the SIB items would range from 0 to 9 with higher scores indicating greater symptom severity. Efficacy of the intervention in reducing self-injurious behaviors would be assessed by a ≥35% reduction in ABC irritability SIB items sub-scale score.

Time frame
Baseline, week 2, week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18

Secondary outcomes

1

Change in Aberrant Behavior Checklist (ABC) irritability non-injurious behaviors items score

The ABC irritability sub-scale consists of 15 items of which 12 focus on depressed mood and irritable behaviors (non-injurious behaviors). Each item takes a score ranging from a minimum of 0 to a maximum of 3. The overall score for the non-injurious behavior items would range from 0 to 36 with higher scores indicating greater symptom severity. Efficacy of the intervention in reducing depressed mood and irritability would be assessed by a ≥35% score reduction in ABC irritability non-injurious behavior items of sub-scale.

Time frame
Baseline, week 2, week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18
2

Change in total score of Parenting Stress Index/Short Form (PSI/SF)

The PSI-SF is a 36-item questionnaire designed to measure stress in the parent-child system and identify those families most in need of follow-up services. The PSI-SF consists of three sub-scales: Parental Distress, Parent-Child Dysfunctional Interaction, and Difficult Child. Each sub-scale consists of 12 items rated from 1 (strongly disagree) to 5 (strongly agree). Sub-scale scores therefore range from 12 to 60, whereas the total score ranges from 36 to 180. High scores on the PSI-SF total score indicate greater levels of stress.

Time frame
Baseline, week 8, week 10, week 18
3

Change in Burden Scale for Family Caregivers score

Burden Scale for Family Caregivers, for assessing subjective burden in informal caregivers. It consists of 10 items, each ranging from 0 to 3, with total score ranging from 0 to 30. High scores indicate greater levels of burden in caregiver.

Time frame
Baseline, week 8, week 10, week 18
4

Change in Sensory Profile score

Sensory profile measure identifies sub-types of individuals based on sensory processing patterns and categorize it as one of the following five profiles: 1- Balanced; 2- Interested; 3- Intense; 4- Mellow until ... ; and 5- Vigilant.

Time frame
Baseline, week 8, week 10, week 18

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Johns Hopkins University

Lead sponsor

Cornelia de Lange Syndrome Foundation

Collaborator

This trial is not recruiting at the moment. You can still explore other options: